The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in Urine

Journal of Molecular Diagnostics

Volumn 2, Issue 3, 2000, Pages 116-123

  Sokolova, Irina A ^a   Halling, Kevin C ^b   Jenkins, Robert B ^b   Burkhardt, Haleh M ^a   Meyer, Reid G ^b   Seelig, Steven A ^a   King, Walter ^a  

^a ABBOTT LABORATORIES   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; ARTICLE; BLADDER TUMOR; CENTROMERE; CHROMOSOME BANDING PATTERN; CLINICAL TRIAL; COLOR; DNA PROBE; EPITHELIUM CELL; EVALUATION; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; HUMAN CHROMOSOME; METABOLISM; METHODOLOGY; PATHOLOGY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; URINE; UROGENITAL TRACT TUMOR;

ANEUPLOIDY; CENTROMERE; CHROMOSOME BANDING; CHROMOSOMES, HUMAN; COLOR; DNA PROBES; EPITHELIAL CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROSCOPY, FLUORESCENCE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 0034252676     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60625-3     Document Type: Article

References (38)

1. Messing EM, Catalona W: Urothelial tumors of the urinary tract. Campbell's Urology, 7th ed. Edited by Walsh PC, Retik AB, Darracott Vaughan E, Wein AJ. Philadelphia, W.B. Saunders Company, 1998, pp 2327-2410
2. Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995, 87:129-133
3. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MGJ, Silberman SR, Butman BT: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997, 158:801-805
4. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon-Gibod L, Ravery V, Le Guludec D, Meulemans A, Conort P, Ishak L: Multicenter trial of the quantitative BTA-TRAK assay in the detectin of bladder cancer. Clin Chem 1999, 45:472-477
5. Maier U, Simak R, Neuhold N: The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995, 48:314-317
6. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997, 50:882-887
7. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC: Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998, 52:398-402
8. Leyh H, Mazeman E: Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 1997, 32:425-428
9. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ: Comparison of screening methods in the detection of bladder cancer. J Urol 1999, 161:388-394
10. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere WR, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA, Brunelle SL: Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997, 50:349-353
11. Schamhart DH, de Reijke TM, van der Poel HG, Witjes JA, de Boer EC, Kurth K, Schalken JA: The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. Eur Urol 1998, 34:99-106
12. Sandberg AA, Berger CS: Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 1994, 151:545-560
13. Sidransky D, Messing E: Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors (review). Urol Clin N Am 1992, 19:629-639
14. Knowles MA: Molecular genetics of bladder cancer (review). Br J Urol 1995, 75 Suppl 1:57-66
15. Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993, 8:1083-1085
16. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788
17. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D: Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995, 55:5213-5216
18. Ruppert JM, Tokino K, Sidransky D: Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 1993, 53: 5093-5095
19. Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM: Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997, 19:84-89
20. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995, 87:1524-1529
21. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G: Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997, 57:2860-2864
22. Sasaki K, Hamano K, Kinjo M, Hara S: Intratumoral heterogeneity in DNA ploidy of bladder carcinomas. Oncology 1992, 49:219-222
23. Shackney SE, Berg G, Simon SR, Cohen J, Amina S, Pommersheim W, Yakulis R, Wang S, Uhl M, Smith CA: Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry 1995, 22:307-316
24. Billerey C, Lamy B, Bittard H, Rozan S, Carbillet JP: Flow cytometry versus urinary cytology in the diagnosis and follow-up of bladder tumors: critical review of a 5-year experience. World J Urol 1993, 11:156-160
25. Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T, Ackerman D, Schmid U, Moch H, Mihatsch MJ, Gasser TC, Sauter G: Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 1999, 59:4658-4661
26. Zhang FF, Arber DA, Wilson TG, Kawachi MH, Slovak ML: Toward the validation of aneusomy detection by fluoresence in situ hybridization in bladder cancer: comparative anlalysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997, 3:2317-2328
27. Wheeless LL, Reeder JE, Han R, O'Connell MJ, Frank IN, Cockett AT, Hopman AH: Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei. Cytometry 1994, 17:319-326
28. Ramaekers FC, Hopman AH: Detection of genetic aberrations in bladder cancer using in situ hybridization. Ann NY Acad Sci 1993, 677:199-213
29. Meloni AM, Peier AM, Haddad FS, Powell IJ, Block AW, Huben RP, Todd I, Potter W, Sandberg AA: A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet 1993, 71:105-118
30. Pycha A, Mian C, Haitel A, Hofbauer J, Wiener H, Marberger M: Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997, 157: 2116-2119
31. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K: Interphase cytogenetics as an adjunct in the cytodiagnosis of urinary bladder carcinoma: a comparative study of cytology, flow cytometry and interphase cytogenetics in bladder washes. Anal Quant Cytol Histol 1994, 16:1-10
32. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K, Bacus JW: Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diag Cytopathol 1995, 13:214-223
33. Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MM, Jenkins RB: Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 1996, 149:1193-1199
34. Bittard H, Lamy B, Billery C: Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J Urol 1996, 1887-1891
35. Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Rukstalis D, Olopade OI: Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res 1994, 54:2060-2063
36. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt H, Hailing AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB: A comparison of cytology and fluorescence in situ hybridization for the detection of bladder cancer. J Urol 2000 (in press)
37. Sauter G, Gasser TC, Moch H, Richter J, Jiang F, Albrecht R, Novotny H, Wagner U, Bubendorf L, Mihatsch MJ: DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res 1997, 25(suppl 1):S37-S43
38. Hopman AH, Moesker O, Smeets AW, Pauwels RP, Vooijs GP, Ramaekers FC: Numerical chromosome 1,7,9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991, 51:644-651